TY - JOUR
T1 - Radioactive gold nanocluster (198-AuNCs) showed inhibitory effects on cancer cells lines
AU - Xuan, Shijin
AU - de Barros, Aline Oliveira da Silva
AU - Nunes, Rogério Chaffin
AU - Ricci-Junior, Eduardo
AU - da Silva, Ademir Xavier
AU - Sahid, Muhammad
AU - Alencar, Luciana Magalhaes Rebelo
AU - dos Santos, Clenilton Costa
AU - Morandi, Veronica
AU - Alexis, Frank
AU - Iram, Surtaj H.
AU - Santos-Oliveira, Ralph
N1 - Publisher Copyright:
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Cancer is a global epidemic disease responsible for over ten millions death worldwide. The early diagnosis and the precise treatment with reduced adverse reactions are the main goal worldwide. In this study, we produced, characterized and evaluated (in vitro) in three different cancer cell lines (protaste, breast and melanoma) a radioactive gold nanocluster (R-AuNC) (198Au25(Capt)18). The pharmacokinetics as the influence in the ABC transporter (MRP1 Efflux Transporter Protein) was also evaluated. The results showed that R-AuNC (198Au25(Capt)18) are capable to kill the cancer cells lines of protaste, breast and melanoma. The pharmacokinetics showed a fast clearance and great volume of distribution, confirming the use of R-AuNC as nanomedicine for cancer treatment. Finally, the ABC transporter assay corroborated that the R-AuNC (198Au25(Capt)18) has no risk of being pumped out of cells by this efflux transporter. The results validate the use of gold nanoparticles as therapeutic nanomedicine for cancer treatment.
AB - Cancer is a global epidemic disease responsible for over ten millions death worldwide. The early diagnosis and the precise treatment with reduced adverse reactions are the main goal worldwide. In this study, we produced, characterized and evaluated (in vitro) in three different cancer cell lines (protaste, breast and melanoma) a radioactive gold nanocluster (R-AuNC) (198Au25(Capt)18). The pharmacokinetics as the influence in the ABC transporter (MRP1 Efflux Transporter Protein) was also evaluated. The results showed that R-AuNC (198Au25(Capt)18) are capable to kill the cancer cells lines of protaste, breast and melanoma. The pharmacokinetics showed a fast clearance and great volume of distribution, confirming the use of R-AuNC as nanomedicine for cancer treatment. Finally, the ABC transporter assay corroborated that the R-AuNC (198Au25(Capt)18) has no risk of being pumped out of cells by this efflux transporter. The results validate the use of gold nanoparticles as therapeutic nanomedicine for cancer treatment.
KW - Radiopharmaceuticals
KW - cancer
KW - nano-radiopharmaceuticals
KW - theranostic
UR - http://www.scopus.com/inward/record.url?scp=85091128421&partnerID=8YFLogxK
U2 - 10.1080/21691401.2020.1821698
DO - 10.1080/21691401.2020.1821698
M3 - Artículo
C2 - 32940067
AN - SCOPUS:85091128421
SN - 2169-1401
VL - 48
SP - 1214
EP - 1221
JO - Artificial Cells, Nanomedicine and Biotechnology
JF - Artificial Cells, Nanomedicine and Biotechnology
IS - 1
ER -
